Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

The goal of this clinical trial\] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with improved disease-free survival (DFS) compared to adjuvant chemotherapy alone.

Trial Details

NCT ID
NCT05797467
Phase
PHASE3
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • FOLFOX chemotherapy regimens
  • Bevacizumab
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Both sexes, aged 18-75 years;
  • Pathologically confirmed pT3-4N2 stage colorectal adenocarcinoma after surgery;
  • ASA grade \< IV and/or ECOG performance status score ≤ 2 points;
  • Fully understand and voluntarily sign the informed consent form for this study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →